More ‘biosimilar’ medicines should be brought to market in the EU because of a regulatory policy shift on the need to carry ...

Biosimilars have the potential to offer more affordable treatment options that contribute to the sustainability of our healthcare system. 2 If you haven’t heard of biosimilars, you’re not alone.

1. The Department of Health has confirmed that a remit referred to NICE enables NICE to decide to apply the same remit, and resulting guidance, to relevant licensed biosimilar products which ...

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

Omlyclo is the first interchangeable biosimilar to omalizumab (Xolair; Genentech, Novartis). Omlyclo was approved to treat the same conditions as Xolair. The FDA approved Celltrion’s omalizumab ...

A biosimilar medicine is a medicine that has a similar, but not identical, active ingredient to the reference (first) medicine. Because of this, a biosimilar should be thought of as being a medicine ...